Clinical Trials in Maryland

Showing 1901-1920 of 11,119 trials

Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

NCT02203695

The primary hypothesis of this study is that outcomes for patients with biochemically recurrent prostate cancer following radical prostatectomy will be improved by the addition of enzalutamide for 6-months compared to standard-of-care salvage radiation therapy to allow for further study in the definitive phase III setting. This study builds on the prior success of high-dose bicalutamide (for 24 months) when combined with salvage external radiation therapy (XRT), while using a newer more potent anti-androgen for a shorter duration of time (6 months) in an effort to minimize adverse effects.

Adenocarcinoma of the Prostate

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins86 participantsStarted Mar 2015

Washington D.C., District of Columbia, United States • Chicago, Illinois, United States • Lafayette, Indiana, United States +6 more locations

Active Not RecruitingPhase 317 miles

Pediatric Patients Aged 4 to 11 Years With APDS

NCT05438407

This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of leniolisib in at least 15 pediatric patients (aged 4 to 11 years) with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).

APDS

Pharming Technologies B.V.15 participantsStarted Feb 2023

Los Angeles, California, United States • Standford, California, United States • Atlanta, Georgia, United States +4 more locations

Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

Pediatric Patients Aged 4 to 11 Years With APDS

Find Trials by Condition in Maryland

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Oral Metformin for Treatment of ABCA4 Retinopathy

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

A Study of XMT-1660 in Participants With Solid Tumors

A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

Using Re-inforcement Learning to Automatically Adapt a Remote Therapy Intervention (RTI) for Reducing Adolescent Violence Involvement

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Safety and Effectiveness Study of OR3O™ Dual Mobility System in THA

Evaluation of the Clinical Performance of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses

Randomized Blinded Evaluation of the Effects of TENS and IFC Compared to a Sham Device and SOC in Patients With Non-Specific CLBP

Access Cannulation Trial II

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Stryker's Surgeon iD Mandible Reconstruction Plates: A Retrospective Post Market Follow Up